In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Arlauckas et al., 2017
In the citing paper
“Most recently, a study revealed another unexpected resistance mechanism to anti-PD-1 therapy in mice whereby tumor-associated macrophages removed the therapeutic antibody from the surface of the T cells in vivo, thus making them once again susceptible to inhibitory signaling through the receptor.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
In the citing paper
“This phenomenon could be partially overcome by administration of Fc-receptor blocking agents prior to treatment (114).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cited by
Items 401–500 of 673
Chen, J., Alduais, Y., & Chen, B. (2021) · Cell Transplantation · doi:10.1177/09636897211041587 · Cited by 12
Truex, N. L., Rondon, A., Rössler, S. L., Hanna, C. C., Cho, Y., Wang, B., Backlund, C. M., Lutz, E. A., Irvine, D. J., & Pentelute, B. L. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00625 · Cited by 12
Yuan, G., Chen, Y., Zhu, P., Deng, Q., Su, K., Liu, J., Wang, Y., Li, R., Li, W., Zang, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37616 · Cited by 12
“Without Fc receptor binding, cadonilimab exhibits minimal antibody-dependent cellular cytotoxicity, cellular phagocytosis, and release of interleukin-6 (IL-6) and interleukin-8 (IL-8) [20].”
BackgroundLAG ‐3—An incompletely understood target in cancer therapy
Leitner, J. M., Radakovics, K., & Steinberger, P. (2024) · The FASEB Journal · doi:10.1096/fj.202401639r · Cited by 12
Sevoflurane depletes macrophages from the melanoma microenvironment
Sztwiertnia, I., Schenz, J., Bomans, K., Schaack, D., Ohnesorge, J., Tamulyte, S., Weigand, M. A., & Uhle, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233789 · Cited by 12
Milenova, I. E., González, M. L., Quixabeira, D. C. A., Santos, J. M., Cervera-Carrascón, V., Dong, W., Hemminki, A., van Beusechem, V. W., van de Ven, R., & de Gruijl, T. D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.277 · Cited by 12
Choi, H., & Na, K. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769393 · Cited by 15
“Notably, the change in GLUT3 level after ICI treatment was different between responders and non-responders in myeloid cells, instead of CD8 T-cells (Figure 4D).”
BackgroundInfluentialZhao, J., Dong, Y., Zhang, Y., Wang, J., & Wang, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114585 · Cited by 12
Villaruz, L. C., Blumenschein, G. R., Otterson, G. A., & Leal, T. A. B. (2023) · Cancer · doi:10.1002/cncr.34683 · Cited by 14
Lim, S. Y., & Rizos, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9757-4 · Cited by 13
Shin, J., Phelan, P. J., Gjoerup, O. V., Bachovchin, W. W., & Bullock, P. A. (2020) · Protein Expression and Purification · doi:10.1016/j.pep.2020.105766 · Cited by 14
“A related advantage of the anti-PD-1 scFv is that full-length anti-PD-1 mAbs are captured within minutes from the surface of T-cells by tumor-associated macrophages and the Fc domains of the mAbs play a critical role in this interaction [82].”
Kurdi, M. E., Mulla, N., Malibary, H. M., Bamaga, A. K., Fadul, M. M., Faizo, E., Hakamy, S., & Baeesa, S. S. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i3.117 · Cited by 13
Mei, Y., Zhang, D., Cao, Y., Hu, J., Gao, X., Liao, W., Huang, C., & Wang, W. (2025) · Materials Today · doi:10.1016/j.mattod.2025.07.021 · Cited by 12
Nie, X., Liu, Y., Yao, X., Zhang, Q., Huang, Y., Mattursun, K., Feng, Y., Liang, T., Yang, L., & Gao, X. (2026) · Nature Cancer · doi:10.1038/s43018-026-01125-2 · Cited by 15
Virus-Based Immuno-Oncology Models
Sitta, J., Claudio, P. P., & Howard, C. M. (2022) · Biomedicines · doi:10.3390/biomedicines10061441 · Cited by 11
“However, researchers have demonstrated predominantly immunosuppressive pro-tumor TMA activity, particularly in poorly ICI responsive tumors [33].”
BackgroundInsights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas
Jani, S., Church, C. D., & Nghiem, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172913 · Cited by 12
“This removal was dependent on the Fcy receptors present on the macrophages and Fc region of the antibodies, suggesting that engineering the Fc region of anti-PD-1 treatments could increase the time of antibody engagement with cancer-specific CD8 T cells (94).”
BackgroundTumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies
Peng, X., Zheng, J., Liu, T., Zhou, Z., Chen, S., Geng, Y., Wang, Z., & Huang, Y. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230712095021 · Cited by 12
Pelka, S., & Guha, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082245 · Cited by 11
Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends
Cheung, P. F., Lutz, M. P., & Siveke, J. T. (2018) · Oncology Research and Treatment · doi:10.1159/000488917 · Cited by 14
The prognostic value of tumor-associated macrophages in glioma patients
Shen, Y., Zheng, D., Hu, D., Ma, B., Cai, C., Chen, W., Zeng, J., Luo, J., Xiao, D., Zhao, Y., et al. (2023) · Medicine · doi:10.1097/md.0000000000035298 · Cited by 13
Smith, A. J., Thurman, R. E., Zeng, W., Grogan, B. M., Lucas, S. Y., Gutierrez, G., Heiser, R. A., Wo, S., Blackmarr, A., Peterson, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1280986 · Cited by 10
Leveraging insights from cancer to improve tuberculosis therapy
Datta, M., Via, L. E., Dartois, V. A., Xu, L., Barry, C. E., & Jain, R. K. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.07.011 · Cited by 12
TAM-tastic: from resistance to resilience in cancer
Low, J. T., Ho, P., & Matsushita, M. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.09.006 · Cited by 10
Rodríguez-Baili, M. C., Palma-Cobo, M., Prucca, C. G., Yáñez‐Mó, M., & Gil, G. A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1548724 · Cited by 10
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies
Alibrahim, M. N., Carbone, A., Alsaleh, N., & Gloghini, A. (2025) · Cancers · doi:10.3390/cancers17142292 · Cited by 14
“For instance, TAMs can physically block CD8+ T-cell migration and even strip PD-1 antibodies from T-cells, neutralizing therapeutic effects [208,209].”
Kwok, T., Silva, I., Korpe, S., Dong, H., & Lancaster, J. N. (2025) · iScience · doi:10.1016/j.isci.2025.113538 · Cited by 12
“14 Previous research has shown that TAMs can sequester anti-PD-1 off T cells, 15 inhibit CD8 + T cell infiltration into tumor nests, 16 and contribute to T cell exhaustion.”
Nagano, M., Saito, K., Kozuka, Y., Ichishi, M., Yuasa, H., Noro, A., Imai, N., Shibusawa, M., Kimoto, M., Ishitobi, M., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12297 · Cited by 13
Abe, K., Shibata, K., Naito, T., Otsuka, A., Karayama, M., Maekawa, M., Miyake, H., Suda, T., & Kawakami, J. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03199-6 · Cited by 11
“The antigenspecific degradation of nivolumab is initiated by binding to PD-1 receptors expressed on lymphocytes [5].”
BackgroundIdentification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer
Li, W., Zhou, K., Li, M., Hu, Q., Wei, W., Liu, L., & Zhao, Q. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02112-4 · Cited by 11
Jiang, M., Qin, B., Li, X., Liu, Y., Guan, G., & You, J. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1837 · Cited by 11
Phenylboronic acid-functionalized chitosan for enabling transmucosal delivery for cancer therapy
Jiang, W., Liang, M., Lei, Q., Deng, D., Li, C., Li, Y., Yuan, S., Wu, K. M., Li, G., & Wu, S. (2023) · Materials & Design · doi:10.1016/j.matdes.2023.111843 · Cited by 10
Izadi, S., Gumpelmair, S., Coelho, P., Duarte, H. O., Gomes, J., Leitner, J. M., Kunnummel, V., Mach, L., Reis, C. A., Steinberger, P., et al. (2023) · Plant Biotechnology Journal · doi:10.1111/pbi.14260 · Cited by 10
“…reduced affinities for most Fc c Rs and C1q (Crescioli et al ., 2016; Jiang et al ., 2011) but still retain high affinity to Fc c RI and binding to Fc c RIIb, which can result in macrophage-mediated phagocytosis of PD-1-positive T cells (Arlauckas et al ., 2017) and decreased anti-tumour activities.”
BackgroundGong, Z., Chen, J., Cheng, J., Sun, C., Jia, Q., Diao, X., & Zhu, B. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.011 · Cited by 10
Hock, B. D., McKenzie, J. L., Strother, R. M., Goddard, L., Butt, L., & Currie, M. J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02636-2 · Cited by 10
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
Wei, Z., & Zhang, Y. (2022) · Cells · doi:10.3390/cells11111758 · Cited by 10
“TAMs are capable of capturing anti-PD-1 antibodies from T-cell membranes [99].”
BackgroundHow to use macrophages to realise the treatment of tumour
Zhang, X., Li, W., Sun, J., Yang, Z., Guan, Q., Wang, R., Li, X., Li, Y., Feng, Y., & Wang, Y. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1775236 · Cited by 10
Pai, S. I., Faquin, W. C., Sadow, P. M., Pittet, M. J., & Weissleder, R. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22305 · Cited by 10
“These phagocytes are increasingly viewed as critical regulators of cancer growth and drug response, but they include various subtypes that can display divergent functions.(37-39) In establishing a myeloid state list,(24) it has become possible to identify myeloid populations that are conserved among patients and whose…”
BackgroundSelf-citationMultidimensional Imaging of Breast Cancer
Rios, A. C., van Rheenen, J., & Scheele, C. L. G. J. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041330 · Cited by 10
Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment
Martinez, F. K., Graffeo, C. S., Carlstrom, L. P., & Link, M. J. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-241834 · Cited by 11
Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time
Almagro, J., & Messal, H. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176594 · Cited by 10
Joo, V., Petrovas, C., de Leval, L., Noto, A., Obéid, M., Fenwick, C. W., & Pantaleo, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213375 · Cited by 11
“In another study, Arlauckas and colleagues showed reduced treatment ef fi cacy with anti-PD-1 transfer and uptake by macrophages in MC38 adenocarcinoma mouse model (66).”
Therapeutic targeting of tumour-associated macrophage receptors
Martins, R. G. A., Tekin, M. M., Cragg, M. S., & Roghanian, A. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf009 · Cited by 11
“Similarly, the therapeutic efficacy of anti-PD-1 has been shown to be reduced due to Fc-mediated trogocytosis of the PD-1 mAb from the surface of T cells by TAMs, and blocking Fc γ RII and Fc γ RIII overcomes this resistance in preclinical models [236].”
Macrophage-centered therapy strategies: A promising weapon in cancer immunotherapy
Wang, S., Liu, J., Cui, Y., Sun, M., Wang, W., Chen, J., Gu, J., & Yang, Z. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101063 · Cited by 18
“…of angiogenesis: TAM-derived VEGF is involved in the development of tumor microvessels and lymphatic vessels and directly mediates angiogenesis in tumor tissues [ 58 ]; (6) Resistance to therapy: M2-like TAMs have been shown to reduce the outcome of immune checkpoint blockade (ICB) therapy [ 59 ].”
Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?
Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L., & Spiliopoulou, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094393 · Cited by 9
“In addition, TAMs can also affect ICI pharmacokinetics and lead to resistance through binding of the Fc domain of the antibody to their Fc γ receptor [52].”
Song, M., Pan, Q., Ding, Y., Zeng, J., Dong, P., Zhao, J., Tang, Y., Li, J., Zhang, Z., He, J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1257 · Cited by 10
Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: A mathematical model
Siewe, N., & Friedman, A. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111297 · Cited by 12
Shin, J., Raissi, S., Phelan, P., & Bullock, P. A. (2022) · Protein Expression and Purification · doi:10.1016/j.pep.2022.106196 · Cited by 9
Hamada, Y., Tanoue, K., Kita, Y., Tanabe, K., Hokonohara, K., Wada, M., Hozaka, Y., Oi, H., Nakayama, C., Higashi, M., et al. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2194011 · Cited by 10
“TAMs are also known to promote PD-1 expression [28], and the decrease in CD163þmonocyte count, including TAMs, in the B-MAB group observed here may be one of the reasons for this.”
BackgroundTada, A., Minami, T., Kitai, H., Higashiguchi, Y., Tokuda, M., Higashiyama, T., Negi, Y., Horio, D., Nakajima, Y., Otsuki, T., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107219 · Cited by 9
Sheban, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183578 · Cited by 11
“Moreover, as discussed earlier, the binding of therapeutic antibodies to macrophage Fc receptors is critical for their clinical output (90).”
BackgroundStructure and functions of Mer, an innate immune checkpoint
Ubil, E., & Zahid, K. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244170 · Cited by 9
Sirbu, D., Luli, S., Leslie, J., Oakley, F., & Benniston, A. C. (2019) · ChemMedChem · doi:10.1002/cmdc.201900181 · Cited by 9
Chawda, C., McMorrow, R., Gaspar, N., Zambito, G., & Mezzanotte, L. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01662-5 · Cited by 11
“To state a few are tumorassociated macrophages (TAM) for silencing tumor-infiltrating CD8 + T cells, [18] natural killer (NK)2cells clearing pulmonary metastasis of anaplastic thyroid cancer cells, [19] the pro-metastatic role of neutrophils, [20] and immunosuppressive activity of tumor-derived dendritic cells, [21] r…”
BackgroundVillanueva, M. T. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.126 · Cited by 9
Sarkar, B., Arlauckas, S. P., Cuccarese, M. F., Garris, C., Weissleder, R., & Rodell, C. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1331480 · Cited by 9
“To examine the cellular biodistribution and induction of IL-12 in vivo , intravital imaging was performed using dorsal skinfold window chambers installed on p40-IRES-eYFP IL-12 reporter mice inoculated with MC38 – H2B-mApple tumors using methods similar to those previously described (4, 99).”
BackgroundMethodInfluentialSelf-citationMacrophages at the Crossroads of Chronic Stress and Cancer
Momčilović, S., Milošević, M. S., Kočović, D. M., Marković, D. C., Zdravković, D., & Vignjević, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146838 · Cited by 10
“The study by Arlauckas et al. [92] revealed that PD-1 − TAM capture anti-PD-1 antibodies from the surface of PD-1 + CD8 + T cells, mediating the resistance to PD-1 blockade.”
Li, L., Zhao, C., Zhao, Z., Han, D., Liao, Y., Liu, Y., Liu, S., Jia, X., Tian, J., Liu, Q., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv2485 · Cited by 13
Wang, B., Li, Y., Shi, M., Liao, Y., Ruan, Y., Han, S., Ma, Y., Guan, X., Yang, R., Dang, T., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102480 · Cited by 14
Zhao, H., Tian, H., Nuerbieke, T., Ma, K., Li, W., Niu, X., Li, J., Ashby, C. R., Chen, Z., Zhou, T., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218690 · Cited by 10
Zhang, Q., Olberg, A., & Sioud, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084282 · Cited by 9
Mechanisms Underlying Tumor-Associated Macrophages (TAMs)-Facilitated Metastasis
Aleebrahim‐Dehkordi, E., Deravi, N., Fallahi, M. S., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_66-1 · Cited by 9
Liu, Y., Wang, Z., Hao, H., Wang, Y.-P., & Hua, L. (2023) · Immunology · doi:10.1111/imm.13647 · Cited by 10
“This acquisition was dependent on Fcγ-receptors (FcγRs) on TAMs, which interacted with the Fc domain of the anti-PD-1 antibodies (Figure 2) [59].”
BackgroundDCLK1 and tuft cells: Immune-related functions and implications for cancer immunotherapy
Ding, L., Weygant, N., Ding, C., Lai, Y., & Li, H. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104118 · Cited by 8
Woo, S. J., Kim, Y., Kang, H., Jung, H., Youn, D. H., Hong, Y., Lee, J. J., & Hong, J. Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02829-8 · Cited by 9
“Previous studies have reported that immunotherapy resistance can be overcome by modulating myeloid cells and TAM [20, 52].”
BackgroundInnovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments
Um‐e‐Kalsoom, Wang, S., Qu, J., & Liu, L. (2024) · Cancer Medicine · doi:10.1002/cam4.70155 · Cited by 8
Macrophage imaging and subset analysis using single-cell RNA sequencing
Arlauckas, S. P., Oh, N., Li, R., Weissleder, R., & Miller, M. A. (2020) · Nanotheranostics · doi:10.7150/ntno.50185 · Cited by 8
“[80] Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS et al.”
BackgroundInfluentialSelf-citationBadiee, P., Maritz, M. F., & Thierry, B. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121845 · Cited by 8
Makrophagen im Melanom – von molekularen Signalen zur therapeutischen Anwendung
Chatziioannou, E., Aydin, S. A., Forchhammer, S., Sinnberg, T. W., & Eigentler, T. (2022) · Die Dermatologie · doi:10.1007/s00105-022-05077-3 · Cited by 10
Zhang, C., Wang, L., Xu, C., Xu, H., & Wu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1079924 · Cited by 11
“Blockade of FcγRs prior to PD-1 mAb administration remarkably prolonged the binding of PD-1 mAb to CD8 T cells and promoted tumor regression (Arlauckas et al., 2017).”
BackgroundA novel 10-gene immune-related lncRNA signature model for the prognosis of colorectal cancer
Ma, B., Cao, L., & Li, Y. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021477 · Cited by 8
Modulating Microenvironments for Treating Glioblastoma
Roberts, L. M., & Munson, J. M. (2020) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-020-00010-z · Cited by 10
Oh, T., Kim, M.-W., Kang, G.-S., Ye, S., Choi, C., Park, W., Hay, M. P., Hirata, H., & Ahn, G. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2025.200 · Cited by 8
“They have further shown that the uptake of PD-1 antibodies by TAM could be prevented by using Fc γ RIIb/ III blocking antibodies or deglycosylated anti–PD-1 antibodies, which have allowed to prolong antibody binding to T cells therefore an improved antitumor response [65].”
Nguyen, T. T., Zhang, B., Zhong, L., Liang, X., & Bo, L. (2025) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70017 · Cited by 10
Bai, R., & Sun, W. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05405-w · Cited by 9
“Arlauckas et al. indicated that PD-1/PD-L1 resistance is often closely related to the accumulation of intratumoral inhibitory macrophages [38].”
Qing, G., Zhang, Y., Wang, Y., Li, X., Luo, T., Zhang, F., Ni, Q., Hu, R., Shan, S., Zhang, H., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv0313 · Cited by 11
Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
Peng, C., Rabold, K., Mulder, W. J. M., Jaeger, M., & Netea-Maier, R. T. (2021) · Cancers · doi:10.3390/cancers13225695 · Cited by 7
Xu, D., Wang, L., Wieczorek, K., Zhang, Y., Wang, Z., Wang, J., Xu, B., Singh, P. K., Wang, Y., Zhang, X., et al. (2022) · Cancers · doi:10.3390/cancers14102511 · Cited by 9
“Anti PD-1 therapies may function through a direct effect on TAMs because both mouse and human TAMs express PD-1 [54] and anti-PD-1 can be transferred to macrophages by Fc-gamma receptors (FcγRs) [55].”
BackgroundAn Overview on Macrophage Targeting: A Promising Approach
Vemuri, V. D., Kushwaha, R., Gollu, G., Mathala, N., Nalla, S., Sasikala, A., & Lekhya, G. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022038827 · Cited by 8
The Interplay between Metabolic Adaptations and Diet in Cancer Immunotherapy
Espelage, L., Wagner, N., Placke, J., Ugurel, S., & Tasdogan, A. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3468 · Cited by 7
Habu, T., Kumagai, S., Bando, H., Fujisawa, T., Mishima, S., Kotani, D., Nakamura, M., Hojo, H., Sakashita, S., Kinoshita, T., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02120-z · Cited by 9
“Other reports have shown that ICI responses are related to the number of TAMs or Tregs [44, 45].”
Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas
Riccardo, F., Barutello, G., Petito, A., Tarone, L., Conti, L., Arigoni, M., Musiu, C., Izzo, S., Volante, M., Longo, D. L., et al. (2020) · Vaccines · doi:10.3390/vaccines8020166 · Cited by 7
“that one of the major causes of this resistance is the accumulation of M2-type macrophages at the tumor site [107,108].”
BackgroundCurrent advances in kidney cancer immunotherapy
Коротаева, А. А., Apanovich, N. V., Александровна, Б. Э., Matveev, V. B., & Karpukhin, A. V. (2019) · Cancer Urology · doi:10.17650/1726-9776-2019-15-4-30-38 · Cited by 7
Feng, Y., Xiao, M., Cao, G., Liu, H., Li, Y., Wang, S., Zijtveld, S., Delvoux, B., Xanthoulea, S., Romano, A., et al. (2022) · Journal of Inflammation · doi:10.1186/s12950-022-00307-w · Cited by 7
Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis
Santoni, M., Liang Cheng, C., Conti, A., Mariani, C., Antonio Lopez-beltran, B., Montironi, R., & Battelli, N. (2017) · European Urology Supplements · doi:10.1016/j.eursup.2017.09.002 · Cited by 7
Fusilier, Z., Simon, F., Calvente, I., Crestey, L., Clément, A., Mathieu, M., Jean-Marie, R., Piastra-Facon, F., Clément, J. G., Lumineau, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.17.633527 · Cited by 11
Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model
Pezeshki, A., Cheville, J. C., Florio, A. B., Leibovich, B. C., & Vasmatzis, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1356144 · Cited by 9
“Additionally, TAMs can decrease ICI ef fi cacy by 1) directly blocking CD8 + T cells ’ anti-tumor functions and tumor in fi ltration ability (25, 27, 33), 2) expressing alternate immune checkpoints (i.e., VISTA) or 3) sequestering ICI antibodies (25, 27, 34 – 36).”
BackgroundFc-optimized checkpoint antibodies for cancer immunotherapy
Dahan, R., & Korman, A. J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.10.008 · Cited by 6
Changes in tumor and cardiac metabolism upon immune checkpoint
Leven, A., Wagner, N., Nienaber, S., Messiha, D., Tasdogan, A., & Ugurel, S. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01092-8 · Cited by 8
“Inhibition of this binding reduces anti-PD-1 antibody levels in TAMs and prolongs their retention in CD8 + T cells, contributing to tumor regression [4].”
Jessel, M.-D., McGreevy, O., McReynolds, L., Dahal, L. N., Gilbert, T. M., Malik, H., Goldring, C. E., & Randle, L. E. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70057 · Cited by 8
Ramasubramanian, T. S., Adstamongkonkul, P., Scribano, C. M., Johnson, C., Caenepeel, S. R., Hrycyniak, L., Vedder, L., Dana, N., Baltes, C., Browning, V. L., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07378-2 · Cited by 7
“Components of the TME, such as cancer-associated fibroblasts [30], tumor-associated macrophages [31], T cells [32] and the tumor cells themselves [33], have been shown to be intricately involved in orchestrating ICI response.”
Improving therapeutic resistance: beginning with targeting the tumor microenvironment
Guan, X., Guan, X., & Jiao, Z. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.2011661 · Cited by 6
Role of tumor-associated macrophages in the breast tumor microenvironment
Mir, M. A., Mir, A. Y., & Mushtaq, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18696-7.00003-8 · Cited by 6
Venkateswaran, S. V., Kreuzaler, P. A., Maclachlan, C., McMahon, G., Greenidge, G., Collinson, L., Bunch, J., & Yuneva, M. O. (2025) · Nature Protocols · doi:10.1038/s41596-024-01118-4 · Cited by 7
“• This protocol combines three imaging modalities: confocal microscopy of fluorescent probes (antibodies), electron microscopy and NanoSIMS enabling cell type identification, characterization of the cellular architecture and extraction of metabolic information.”
Carter, M. J., Bogdanov, Y. D., Smith, R. C. G., Cox, K. L., Frampton, S., Ferson, L., Foxall, R. B., Hussain, K., Strefford, J. C., Beers, S. A., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf109 · Cited by 8
Ding, X., Mi, L., Song, Y., Liu, W., Yu, H., Lin, N., & Zhu, J. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i21.6041 · Cited by 6
Zhang, Y., LIM, D. J., Cai, Z., Peng, J., Jia, B., Chu, G., Zhang, F., Dong, C., & Feng, Z. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113779 · Cited by 6
Advances in intravital imaging of liver immunity using optical microscopy and labeling methods
Yuan, X., Xiang, Y., Dai, B., & Zhang, Z. (2023) · iRadiology · doi:10.1002/ird3.7 · Cited by 6
PD‐1 blocking antibodies moonlighting as killers
Leitner, J. M., Battin, C., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2021) · European Journal of Immunology · doi:10.1002/eji.202149276 · Cited by 6
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Salkeni, M. A., Shin, J. Y., & Gulley, J. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_2 · Cited by 6
Huang, Z., Zhu, R.-H., Xin, J.-Y., & Li, K. (2022) · European Radiology · doi:10.1007/s00330-022-09339-5 · Cited by 8
“The hyper-enhanced rim at the Kupffer phase represents the accumulation of tumor-related macrophages, and these cells may favor tumor development and therefore resistance to treatment [10].”
Background
Metadata
- Authors
- Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
- Massachusetts General Hospital (US)
- Corresponding author
- Arlauckas, Sean P.
- Garris, Christopher S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-10
- Volume
- 9
- Issue
- 389
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5734617
- OpenAlex
- W2612649234
- Cited by
- 669
- References
- 55
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 76 · 2023: 75 · 2022: 84 · 2021: 98 · 2020: 87 · 2019: 62 · 2018: 50 · 2017: 29
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- National Institutes of Health (award301192, 5P50CA086355, award301190, R01AI084880, award301193, R21CA190344, award301191, U54-CA151884)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cell activation, tumor regression, in vivo imaging, target engagement
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunotherapy, Mice, Inbred C57BL, Receptors, IgG, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.